Literature DB >> 22669132

KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.

Bríd M Ryan, Ana I Robles, Curtis C Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669132      PMCID： PMC4132878          DOI： 10.1158/1078-0432.CCR-12-0250

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.

Authors:  A Ruzzo; E Canestrari; N Galluccio; D Santini; B Vincenzi; G Tonini; M Magnani; F Graziano
Journal:  Ann Oncol       Date:  2010-10-06       Impact factor: 32.976

2.  Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.

Authors:  F Graziano; E Canestrari; F Loupakis; A Ruzzo; N Galluccio; D Santini; M Rocchi; B Vincenzi; L Salvatore; C Cremolini; C Spoto; V Catalano; S D'Emidio; P Giordani; G Tonini; A Falcone; M Magnani
Journal:  Pharmacogenomics J       Date:  2010-02-23       Impact factor: 3.550

3.  KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

Authors:  W Zhang; M J Labonte; H-J Lenz
Journal:  Ann Oncol       Date:  2011-01-28       Impact factor: 32.976

4.  A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Authors:  Kim M Smits; Trupti Paranjape; Sunitha Nallur; Kim A D Wouters; Matty P Weijenberg; Leo J Schouten; Piet A van den Brandt; Fred T Bosman; Joanne B Weidhaas; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2011-10-12       Impact factor: 12.531

5.  A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

Authors:  W Zhang; T Winder; Y Ning; A Pohl; D Yang; M Kahn; G Lurje; M J LaBonte; P M Wilson; M A Gordon; S Hu-Lieskovan; D J Mauro; C Langer; E K Rowinsky; H-J Lenz
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976
  5 in total
  14 in total

1.  KRAS polymorphisms are associated with survival of CRC in Chinese population.

Authors:  Qiong Dai; Hui Lian Wei; Juan Huang; Tie Jun Zhou; Li Chai; Zhi-Hui Yang
Journal:  Tumour Biol       Date:  2015-10-29

2.  A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Authors:  Zenia Saridaki; Joanne B Weidhaas; Heinz-Josef Lenz; Pierre Laurent-Puig; Bart Jacobs; Jef De Schutter; Wendy De Roock; David W Salzman; Wu Zhang; Dongyun Yang; Camilla Pilati; Olivier Bouché; Hubert Piessevaux; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2014-09-01       Impact factor: 12.531

Review 3.  SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Authors:  Carina Preskill; Joanne B Weidhaas
Journal:  Crit Rev Oncog       Date:  2013

Review 4.  The hallmarks of premalignant conditions: a molecular basis for cancer prevention.

Authors:  Bríd M Ryan; Jessica M Faupel-Badger
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

5.  Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Authors:  Dan Sha; Adam M Lee; Qian Shi; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

6.  Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.

Authors:  Janne B Kjersem; Tone Ikdahl; Tormod Guren; Eva Skovlund; Halfdan Sorbye; Julian Hamfjord; Per Pfeiffer; Bengt Glimelius; Christian Kersten; Hiroko Solvang; Kjell M Tveit; Elin H Kure
Journal:  BMC Cancer       Date:  2012-11-20       Impact factor: 4.430

7.  Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Authors:  F Sclafani; I Chau; D Cunningham; C Peckitt; A Lampis; J C Hahne; C Braconi; J Tabernero; B Glimelius; A Cervantes; R Begum; D Gonzalez De Castro; S Hulkki Wilson; Z Eltahir; A Wotherspoon; D Tait; G Brown; J Oates; N Valeri
Journal:  Ann Oncol       Date:  2015-07-10       Impact factor: 32.976

Review 8.  MicroRNA dysregulation as a prognostic biomarker in colorectal cancer.

Authors:  Yujuan Dong; Jun Yu; Simon Sm Ng
Journal:  Cancer Manag Res       Date:  2014-10-14       Impact factor: 3.989

9.  Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma.

Authors:  Sonja Marinović; Anita Škrtić; Tina Catela Ivković; Mirko Poljak; Sanja Kapitanović
Journal:  Hum Cell       Date:  2021-07-07       Impact factor: 4.174

Review 10.  Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.

Authors:  Scott M Langevin; Brock C Christensen
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.